The Trump administration is considering rolling back an Obama-era policy that supporters say successfully lowered some prescription drug prices, but that opponents say discourages innovation.
Since taking effect last year, the policy has affected how Medicare pays for so-called biosimilars, which are highly similar versions of biologic drugs like Humira and Rituxan that are manufactured in living cells or microorganisms. In essence, the policy attempted to use certain Medicare payments to encourage more price competition among such drugs.
About the Author Reprints
